South Korea's Green Cross Holdings and POSCO Capital joined to buy a $7.5 million stake in U.S.-based Juventas Therapeutics, pushing a regenerative and biologics growth strategy that has seen recent deals in China and Russia.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
More than a year after flagging its interest in a B round, Cleveland Clinic-spinout Juventas Therapeutics has put the final pieces together for a $22.2 million raise.
The CEO of Juventas Therapeutics, a spinoff of the Cleveland Clinic, says that now that the company has wrapped a successful Phase I trial of its lead stem cell therapy, it plans to raise $25 million